Barely Significant
← all excerpts

Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate-Effect Variants.

Circulation · 2025 · PMC12513046 · PMID 40879562

Europe PMCDOI
3
hedged sentences
0.0001
closest p · 0.0× alpha
0.0630
boldest claim

The sentences

marginally significantP <0.0001actually significant
Enrichment analysis of these null variants in heterozygosity against gnomAD-NFE revealed a marginally significant enrichment (OR, 2.39 [95% CI, 1.65–3.47], P <0.0001) that was not validated against internal controls (OR 1.34 95% CI, 0.74–2.42], P =0.337; Table S9 ), reinforcing our approach of treating cases with heterozygous null variants in TRIM63 as negative.

also in 26,082 other papers

a nonsignificant trendP =0.063so close (0.05 < p ≤ 0.1)
No statistically significant differences were observed, although a nonsignificant trend toward greater LVMWT ( P =0.063) and higher MACE incidence ( P =0.141) was noted in carriers of sarcomeric IEVs.

also in 5,406 other papers

borderline significanceno p-value reported
Three of the variants identified in the SHaRe study ( MYBPC3 :p.Arg810His, p.Asp610His, and p.Asp605Asn) showed borderline significance when we compared the HCM cohort with our internal controls.

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.